AP2416A - Stabilized pharmaceutical compositions comprising fesoterodine. - Google Patents

Stabilized pharmaceutical compositions comprising fesoterodine.

Info

Publication number
AP2416A
AP2416A AP2008004673A AP2008004673A AP2416A AP 2416 A AP2416 A AP 2416A AP 2008004673 A AP2008004673 A AP 2008004673A AP 2008004673 A AP2008004673 A AP 2008004673A AP 2416 A AP2416 A AP 2416A
Authority
AP
ARIPO
Prior art keywords
fesoterodine
pharmaceutical compositions
stabilized pharmaceutical
stabilized
compositions
Prior art date
Application number
AP2008004673A
Other languages
English (en)
Other versions
AP2008004673A0 (en
Inventor
Christoph Arth
Fatima Bicane
Meike Irngartinger
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2416(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of AP2008004673A0 publication Critical patent/AP2008004673A0/xx
Application granted granted Critical
Publication of AP2416A publication Critical patent/AP2416A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2008004673A 2006-06-09 2007-06-06 Stabilized pharmaceutical compositions comprising fesoterodine. AP2416A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06011942 2006-06-09
EP06011943 2006-06-09
EP06011941 2006-06-09
PCT/EP2007/055582 WO2007141298A1 (en) 2006-06-09 2007-06-06 Stabilized pharmaceutical compositions comprising fesoterodine

Publications (2)

Publication Number Publication Date
AP2008004673A0 AP2008004673A0 (en) 2008-12-31
AP2416A true AP2416A (en) 2012-06-01

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004673A AP2416A (en) 2006-06-09 2007-06-06 Stabilized pharmaceutical compositions comprising fesoterodine.

Country Status (38)

Country Link
EP (1) EP2029134B1 (ja)
JP (2) JP4743321B2 (ja)
KR (1) KR101316773B1 (ja)
CN (1) CN101466371B (ja)
AP (1) AP2416A (ja)
AR (1) AR061289A1 (ja)
AT (1) ATE517619T1 (ja)
AU (1) AU2007255408B2 (ja)
BR (1) BRPI0712865B1 (ja)
CA (1) CA2652712C (ja)
CR (1) CR10494A (ja)
CU (1) CU23850B1 (ja)
CY (1) CY1111934T1 (ja)
DK (1) DK2029134T3 (ja)
EA (1) EA015909B9 (ja)
EC (1) ECSP089010A (ja)
ES (1) ES2370943T3 (ja)
GT (1) GT200800276A (ja)
HK (1) HK1128626A1 (ja)
HR (1) HRP20110776T1 (ja)
IL (2) IL195732A (ja)
MA (1) MA30504B1 (ja)
MX (1) MX2008015736A (ja)
MY (1) MY146574A (ja)
NI (1) NI200800318A (ja)
NL (1) NL2000690C2 (ja)
NO (1) NO341980B1 (ja)
NZ (1) NZ572616A (ja)
PE (2) PE20120476A1 (ja)
PL (1) PL2029134T3 (ja)
PT (1) PT2029134E (ja)
RS (1) RS51973B (ja)
SI (1) SI2029134T1 (ja)
TN (1) TNSN08505A1 (ja)
TW (2) TWI520735B (ja)
UY (1) UY30394A1 (ja)
WO (1) WO2007141298A1 (ja)
ZA (1) ZA200806411B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086103A1 (en) * 2008-04-04 2011-04-14 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
IT1392082B1 (it) 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
EP2416761B1 (de) 2009-05-11 2015-02-11 ratiopharm GmbH Desfesoterodin in form eines weinsäuresalzes
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
WO2013054337A1 (en) * 2011-07-04 2013-04-18 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
EP2780317A2 (en) * 2012-05-18 2014-09-24 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
WO2014006636A2 (en) * 2012-07-02 2014-01-09 Hetero Research Foundation Stable compositions of fesoterodine
MX2015005637A (es) 2012-11-02 2016-02-03 Murray And Poole Entpr Ltd Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina.
AU2014255434B2 (en) 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
CA3094551C (en) 2018-04-26 2024-01-02 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2023145486A1 (ja) * 2022-01-28 2023-08-03 沢井製薬株式会社 フェソテロジンフマル酸塩含有製剤の製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
WO2001035957A1 (de) * 1999-11-16 2001-05-25 Sanol Arznei Schwarz Gmbh Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen
WO2003099268A1 (de) * 2002-05-29 2003-12-04 Grünenthal GmbH Kombination ausgewählter opioide mit anderen wirkstoffen zur therapie der harninkontinenz

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
WO2001035957A1 (de) * 1999-11-16 2001-05-25 Sanol Arznei Schwarz Gmbh Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen
WO2003099268A1 (de) * 2002-05-29 2003-12-04 Grünenthal GmbH Kombination ausgewählter opioide mit anderen wirkstoffen zur therapie der harninkontinenz

Also Published As

Publication number Publication date
ES2370943T3 (es) 2011-12-23
PE20120476A1 (es) 2012-04-20
GT200800276A (es) 2009-06-18
EA200802444A1 (ru) 2009-06-30
PE20080331A1 (es) 2008-06-19
BRPI0712865B1 (pt) 2021-08-17
RS51973B (en) 2012-02-29
PL2029134T3 (pl) 2011-12-30
CY1111934T1 (el) 2015-11-04
BRPI0712865A2 (pt) 2012-12-18
AP2008004673A0 (en) 2008-12-31
NI200800318A (es) 2011-01-12
JP2009539802A (ja) 2009-11-19
ECSP089010A (es) 2009-01-30
EP2029134A1 (en) 2009-03-04
EA015909B9 (ru) 2012-03-30
MY146574A (en) 2012-08-30
WO2007141298A1 (en) 2007-12-13
ATE517619T1 (de) 2011-08-15
SI2029134T1 (sl) 2012-01-31
DK2029134T3 (da) 2011-10-17
CN101466371A (zh) 2009-06-24
MA30504B1 (fr) 2009-06-01
CA2652712C (en) 2014-04-01
EP2029134B1 (en) 2011-07-27
TNSN08505A1 (fr) 2010-04-14
HK1128626A1 (en) 2009-11-06
TWI397409B (zh) 2013-06-01
JP4743321B2 (ja) 2011-08-10
CN101466371B (zh) 2011-10-05
TW201336491A (zh) 2013-09-16
TW200814992A (en) 2008-04-01
EA015909B1 (ru) 2011-12-30
AU2007255408B2 (en) 2013-03-14
NZ572616A (en) 2010-11-26
CU20080235A7 (es) 2011-04-26
TWI520735B (zh) 2016-02-11
MX2008015736A (es) 2009-01-09
NL2000690C2 (nl) 2008-04-01
IL195732A (en) 2013-09-30
UY30394A1 (es) 2007-11-30
ZA200806411B (en) 2009-05-27
IL195732A0 (en) 2009-09-01
IL220800A (en) 2015-03-31
NO20090141L (no) 2009-01-09
NL2000690A1 (nl) 2007-12-11
JP2011140498A (ja) 2011-07-21
NO341980B1 (no) 2018-03-05
PT2029134E (pt) 2011-11-02
AR061289A1 (es) 2008-08-20
HRP20110776T1 (hr) 2011-11-30
JP4781489B2 (ja) 2011-09-28
KR101316773B1 (ko) 2013-10-15
AU2007255408A1 (en) 2007-12-13
CA2652712A1 (en) 2007-12-13
CR10494A (es) 2009-01-19
CU23850B1 (es) 2012-10-15
KR20090026135A (ko) 2009-03-11

Similar Documents

Publication Publication Date Title
AP2416A (en) Stabilized pharmaceutical compositions comprising fesoterodine.
HK1244267A1 (zh) 包含(r)-n-甲基納曲酮的藥物組合物
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
LT3984528T (lt) Farmacinė kompozicija, apimanti nilotinibą
GB0713625D0 (en) Pharmaceutical compositions
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
HK1138732A1 (en) Pharmaceutical compositions
IL188352A0 (en) Pharmaceutical compositions
GB0523810D0 (en) Pharmaceutical compositions
GB0522045D0 (en) Pharmaceutical compositions
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
IL192091A0 (en) Pharmaceutical compositions
IL198160A0 (en) Pharmaceutical formulations
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0514259D0 (en) Pharmaceutical compositions
HU0600939D0 (en) Pharmaceutical compositions
GB0622964D0 (en) Pharmaceutical compositions
HU0600938D0 (en) Pharmaceutical compositions
ZA200808030B (en) Pharmaceutical compositions
GB0609941D0 (en) Pharmaceutical compositions
GB0621623D0 (en) Pharmaceutical compositions
GB0611079D0 (en) Pharmaceutical compositions
SI1948155T1 (sl) Farmacevtski sestavki ki obsegajo droksidopo